What is the relapse rate of myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD) in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Relapse Rate in MOGAD

The relapse rate in adults with MOGAD ranges from 36-57%, with most relapses occurring within the first year after diagnosis, and approximately 50-60% of patients experience relapses during corticosteroid dose reduction.

Overall Relapse Rates by Population

  • Adult MOGAD patients have a relapse rate of approximately 56-57% in North American cohorts, which is notably higher than previously reported rates 1, 2
  • The 8-year cumulative relapse risk is 36.3% in a large UK prospective cohort, though this may underestimate true relapse rates as it represents incident cases diagnosed before a second attack 3
  • Pediatric MOGAD shows a 46% relapse rate over a mean follow-up of 3.9 years, with female sex and Hispanic/Latino ethnicity associated with higher relapse risk 4

Critical Timing Considerations

  • Most relapses occur within the first year after diagnosis, making this a high-risk period requiring close monitoring 1
  • 40% of first relapses occur immediately following withdrawal of acute treatment, particularly after stopping corticosteroids from the initial attack 2
  • 50-60% of patients relapse during corticosteroid dose reduction, which is why maintenance immunosuppression should be initiated early rather than waiting for a second attack 5

Factors Associated with Higher Relapse Risk

Demographics

  • Young adult age (18-40 years) carries 2.7-fold higher relapse risk compared to older adults (>40 years) 3
  • Female sex increases relapse risk by 66% compared to males in pediatric cohorts 4
  • Hispanic/Latino ethnicity increases relapse risk by 77% compared to non-Hispanic patients 4

Clinical Presentation

  • Optic neuritis at onset is associated with 2.66-fold higher relapse risk compared to transverse myelitis at onset, though this association loses statistical significance when adjusted for follow-on corticosteroid use 3
  • Any transverse myelitis at onset (alone or combined with other presentations) reduces relapse risk by 59% compared to presentations without myelitis 3
  • ADEM presentation is more common in children (68% of those <12 years) but does not clearly predict relapse risk 3

Monophasic vs. Relapsing Disease

  • 43-44% of MOGAD cases follow a monophasic course, meaning they never relapse after the initial attack 1, 2
  • Predicting which patients will have monophasic disease remains extremely difficult, as no single factor reliably distinguishes monophasic from relapsing courses at disease onset 2
  • MOG-IgG antibody titers, CSF findings, and initial presentation phenotype do not reliably predict relapse risk in most studies 2
  • 5-10% of patients may convert to seronegative status, and some of these patients can still relapse, indicating antibody disappearance does not guarantee monophasic disease 2

Impact of Maintenance Therapy on Relapse Rates

Without Maintenance Therapy

  • The annualized relapse rate off treatment ranges from 0.97-1.0 relapses per year in relapsing patients 2
  • 64% of patients who started disease-modifying therapy before their first relapse remained monophasic, suggesting early treatment may prevent relapses 2

With Maintenance Therapy

  • Maintenance prednisolone reduces relapse risk by 67% compared to no treatment when adjusted for covariates 3
  • First-line immunosuppression (prednisolone, nonsteroidal agents, or combined) reduces relapse risk by 49% compared to no treatment 3
  • IVIG shows the lowest annualized relapse rate of 0.13 with 72% relapse-freedom probability after at least 6 months of therapy 6
  • Mycophenolate mofetil has an annualized relapse rate of 0.32 with 49% relapse-freedom probability, and shows particularly good efficacy in pediatric-onset disease (ARR 0.15) 6
  • B-cell depletion therapy has an annualized relapse rate of 0.51 with only 33% relapse-freedom probability, which is surprisingly lower efficacy than other agents 6
  • Rituximab or IVIG initiated shortly after onset is associated with lower risk of second events in pediatric patients 4

Common Pitfalls in Assessing Relapse Risk

  • Do not assume low antibody titers predict monophasic disease, as titers fluctuate with disease activity and treatment status 5
  • Do not stop monitoring patients who become seronegative, as some seronegative patients still relapse 2
  • Do not taper steroids rapidly after the acute attack, as 40% of first relapses occur during treatment withdrawal 2
  • Do not wait for a second attack to initiate maintenance therapy in high-risk patients (young adults, females, Hispanic/Latino ethnicity, optic neuritis presentation), as early treatment may prevent relapses 4, 3
  • Recognize that 50% of patients on disease-modifying therapy continue to have disease activity, requiring treatment adjustment, so ongoing monitoring is essential even on maintenance therapy 2

References

5
Guideline

Treatment of MOG-Positive Disease with Bilateral Ptosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended treatment for a patient with optic neuritis and positive MOG (Myelin Oligodendrocyte Glycoprotein) antibody after initial treatment with intravenous (IV) Methylprednisolone (methylprednisolone) for 5 days?
What are the current treatment recommendations for relapse in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)?
What to do for a patient with suspected Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) who received intravenous (IV) methylprednisolone (prednisolone) and a 2-day course of Intravenous Immunoglobulin (IVIG) one week ago, is currently on a tapering dose of oral prednisolone, and presents with a suspected relapse at a facility without plasma exchange services?
What is the recommended post‑operative medical management, imaging surveillance, and lifestyle guidance after aortic valve, root, or ascending aorta replacement?
I have pharyngeal irritation after drinking raspberry herbal tea while experiencing allergic rhinitis; what is the likely cause and appropriate management?
What is the recommended therapy and dosing strategy for sacubitril‑valsartan in an adult with chronic congestive heart failure (EF ≤40%, NYHA II‑IV) and coexisting hypertension?
What is the recommended treatment plan for a patient with type 2 diabetes, hypertension, chronic kidney disease, and a reduced left‑ventricular ejection fraction of about 43 %?
What is the appropriate iron sucrose dosing regimen for a 45‑kg adolescent with iron‑deficiency anemia?
What could cause generalized edema despite normal routine laboratory results, and how should it be evaluated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.